The 3-way competition of Pfizer, Lilly and Astellas in the oral RA treatment
As Pfizer, Lilly and Astellas entered the domestic oral rheumatoid arthritis treatment market, the 3-way competition has been formed.
Astellas Korea was recently approved for a clinical trial on its rheumatoid arthritis candidate treatment ‘ASP015K’ from the Ministry of Food and Drug Safety.
AS...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
